Can a new tablet formulation improve how a kidney disease drug is absorbed?

NCT ID NCT07722585

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a new tablet version of the experimental drug nurandociguat, which is being developed for chronic kidney disease. Healthy volunteers will receive both the old and new tablets, with and without a high-fat meal, to compare how the drug enters the bloodstream. The goal is to see if the new formulation works similarly and how food affects its absorption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nurandociguat (BAY3283142) tablets
What this could lead to: If the new tablet works as well as the old one, it could offer a more convenient option for future chronic kidney disease treatments.
What could go wrong: This is an early-stage study in healthy people, not patients. It only measures drug levels, not whether the drug actually helps kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CRS Clinical Research Services Berlin GmbH

Berlin, 13627, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.